September 2019 in “Journal of Investigative Dermatology” In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” This article discusses the potential of oral tofacitinib as a treatment for atopic dermatitis, alopecia areata, and vitiligo, without presenting new clinical results.
10 citations
,
December 2024 in “Allergy” This study found that tralokinumab effectively reduced the severity of moderate-to-severe atopic dermatitis over 28 weeks in adults, with significant improvements in clinical outcomes and biological markers, although 27.4% of patients discontinued treatment due to adverse events or ineffectiveness.
1 citations
,
May 2023 in “The Journal of Dermatology” This case report describes a patient with severe alopecia totalis and atopic dermatitis who showed almost complete hair regrowth and improved skin lesions after receiving subcutaneous allergen-specific immunotherapy using house dust mites.
November 2025 in “The Journal of Dermatology” In this case report, a Japanese woman with both atopic dermatitis and alopecia areata showed improvement in both conditions following treatment with nemolizumab.
